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Background
Once-daily fixed-dose combinations ABC/3TC and
TDF/FTC are the preferred backbones in Europe [1].
Long-term (>2 years) efficacy and safety of these com-
pounds in simplification strategies are unknown.
Methods
333 HIV-1-infected adults on3 T C - c o n t a i n i n gt r i p l e
regimens with <200 copies/mL for at least 6 months
had their NRTI backbone randomly switched to either
ABC/3TC or TDF/FTC. Pre-planned results at 1 year
have been already published [2]. Treatment failure
(defined as virological failure, discontinuation of study
therapy, withdrawal of consent, lost to follow-up, pro-
gression to AIDS, or death), virological failure (defined
as confirmed plasma HIV-1 RNA >200 copies/mL),
adverse events, and changes in CD4 cells, fasting plasma
lipids, glomerular filtration rate (GFR) (Cockcroft-
Gault), and transaminases at 3 years were compared
between arms.
Results
Treatment failure increased from 32 (19%) to 58 (35%)
patients on ABC/3TC and from 22 (13%) to 61 (37%)
patients on TDF/FTC at 1 and 3 years, respectively (HR
for ABC/3TC treatment failure at 3 years 0.99, 95% CI
0.69-1.41). The most common reasons for treatment
failure at 3 years in both arms were lost to follow-up/
withdrawal of consent (68 patients, 20%) or discontinua-
tion of study drugs for reasons other than adverse
events (15 patients, 5%). Total discontinuations due to
adverse events increased from 17 at 1-year to 18
patients at 3-years on ABC/3TC and from 9 at 1-year to
10 patients at 3-years on TDF/FTC. Total virological
failures increased from 4 at 1-year to 6 patients at 3-
years on ABC/3TC while no patient on TDF/FTC devel-
oped virological failure at 1-year and through 3-years
(HR for ABC/3TC virological failure at 3 years 3.59,
95% CI 0.77-6.42). Change from baseline (mg/dL) in tri-
glycerides (+1 vs -29, P=0.008), total cholesterol (+12 vs
-12, P<0.001), LDL-cholesterol (+1 vs -1, P<0.001), and
HDL-cholesterol (+3 vs -2, P<0.001) were increased in
patients on ABC/3TC compared with decreases in
patients on TDF/FTC, although total-to-HDL choles-
terol ratio remained almost identical in both arms.
There were no significant changes in GFR or transami-
nases in each arm at 3-years.
Conclusion
From the 1-year analysis, we observed two additional
virological failures in patients on ABC/3TC; there were
no virological failures in patients on TDF/FTC over 3
years. Through 3 years long-term safety/tolerability was
very good. Differential lipid effects between arms were
maintained at 3 years.
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